ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Sjögren's Syndrome – Basic and Clinical Science Poster

Date: Monday, November 14, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM
Abstract Number: 2044
Abnormalities of Extracellular Matrix Modeling Gene Expression in Salivary Gland Epithelial Cells of Patients with Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2046
Agreement Between Labial Biopsy and the OMERACT Grey-scale Ultrasound Scoring System for Salivary Glands in a Single-center Cohort of Patients with Suspected Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2020
Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease
1:00PM-3:00PM
Abstract Number: 2017
Characteristics and Prognosis Factors of Relapse or Death for Non-Hodgkin Lymphomas in Primary Sjögren Syndrome
1:00PM-3:00PM
Abstract Number: 2037
Childhood-onset Sjögren’s Syndrome Is Characterised by Dysregulated of B and T Memory Cell Frequencies: A Pilot Immunophenotyping Analysis of This Rare Disease Phenotype
1:00PM-3:00PM
Abstract Number: 2030
Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2036
Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon
1:00PM-3:00PM
Abstract Number: 2047
Discriminative Power of Salivary Gland Ultrasound in Relation to Symptom-based Endotypes in Suspected and Definite Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2029
Distinctive Clinical Profiles Associated with anti-SSA/Ro60, anti-Ro52/TRIM21 and Anti-SSB/La Reactivity
1:00PM-3:00PM
Abstract Number: 2045
Does Ancestry Influence Primary Sjögren’s Syndrome Phenotype or Severity?
1:00PM-3:00PM
Abstract Number: 2021
Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2031
Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
1:00PM-3:00PM
Abstract Number: 2035
Elucidating the Factors That Influence the Use of Minor Salivary Gland Biopsy for the Evaluation of Childhood Sjögren’s Disease
1:00PM-3:00PM
Abstract Number: 2019
Fine Mapping of the Sjögren’s Disease and Systemic Lupus Erythematosus DDX6-CXCR5 Risk Interval Reveals Common SNPs with Functional Significance in Immune and Salivary Gland Cells
1:00PM-3:00PM
Abstract Number: 2018
Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2049
ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive
1:00PM-3:00PM
Abstract Number: 2027
Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2032
Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2040
Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
1:00PM-3:00PM
Abstract Number: 2025
Natural History of Sjögren’s Disease from the National Institutes of Health Cohort
1:00PM-3:00PM
Abstract Number: 2033
Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology
1:00PM-3:00PM
Abstract Number: 2022
Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study
1:00PM-3:00PM
Abstract Number: 2023
Salivary Autoantibodies in Sicca Patients Are Associated with Dry Symptoms
1:00PM-3:00PM
Abstract Number: 2024
Salivary Gland Ultrasound May Lead to a More Accurate Stratification of Patients with the Same Serological Profile in Sjögren’s Syndrome: Towards a Personalized Approach
1:00PM-3:00PM
Abstract Number: 2048
Serology Driven Pulmonary Phenotype Characterization of Sjögren Syndrome-associated Interstitial Lung Disease: A Monocentric Cohort Study
1:00PM-3:00PM
Abstract Number: 2026
Serum and Tear Autoantibodies from nor Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2041
Single Cell Atlas of Minor Salivary Glands Reveals Key Differential Cellular and Functional Players in Sjögren’s and Sicca Syndrome
1:00PM-3:00PM
Abstract Number: 2038
Single Cell RNA Sequencing Points to a Role for Fibroblasts Early in Salivary Gland Dysfunction in Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2042
Sjögren’s Disease and Mitochondrial Function
1:00PM-3:00PM
Abstract Number: 2050
Stratification on Baseline Interferon Scores and Use of CRESS to Improve the Design of Future Trials in Sjögren’s Syndrome: Post Hoc Analysis from a Randomized Controlled Trial
1:00PM-3:00PM
Abstract Number: 2051
Targeting Janus Kinase Pathway in Sjogren’s Disease Corrects IFN-Driven Inflammation and Epithelial Dysfunction
1:00PM-3:00PM
Abstract Number: 2039
The Tubarial Glands Resemble the Palatal Salivary Glands Based on Further Histological Characterization, and May Represent an Organ of Interest in Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2028
The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2043
What Does Isolated Anti-Ro52 Antibody Positivity Mean in Sjögren’s Syndrome?
1:00PM-3:00PM
Abstract Number: 2034
What Is the Best Initial Screening for Suspected Sjögren’s Disease?

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology